Successful treatment for conventional treatment-resistant dermatomyositis-associated interstitial lung disease with adalimumab

Rheumatology International

Volumn 32, Issue 11, 2012, Pages 3587-3590

  Park, Jin Kyoung ^a   Yoo, Han Gyul ^b   Ahn, Dae Seon ^a   Jeon, Hyun Soon ^a   Yoo, Wan Hee ^a  

^a Chonbuk National University Medical School and Hospital   (South Korea)

^b UNIVERSITY OF RHODE ISLAND   (United States)

Author keywords

Adalimumab; Dermatomyositis; Interstitial lung disease

Indexed keywords

ADALIMUMAB; ANTINUCLEAR ANTIBODY; AZATHIOPRINE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; FRUCTOSE BISPHOSPHATE ALDOLASE; JO 1 ANTIBODY; LACTATE DEHYDROGENASE; METHOTREXATE; PREDNISOLONE;

ADULT; AMINOTRANSFERASE BLOOD LEVEL; ANTIBODY TITER; ARTICLE; CASE REPORT; CORTICOSTEROID THERAPY; DERMATOMYOSITIS; DERMATOMYOSITIS ASSOCIATED INTERSTITIAL LUNG DISEASE; DISEASE ASSOCIATION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ELECTROMYOGRAPHY; ENZYME BLOOD LEVEL; ERYTHEMA; EYELID EDEMA; FEMALE; HIGH RESOLUTION COMPUTER TOMOGRAPHY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; HYPERKERATOSIS; IMMUNOSUPPRESSIVE TREATMENT; INTERSTITIAL LUNG DISEASE; LACTATE DEHYDROGENASE BLOOD LEVEL; MUSCLE BIOPSY; MUSCLE WEAKNESS; MYOPATHY; PRIORITY JOURNAL; RASH; SIDE EFFECT; SKIN BIOPSY; SKIN DISCOLORATION; THORAX RADIOGRAPHY; TREATMENT RESPONSE;

ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL, HUMANIZED; DERMATOMYOSITIS; FEMALE; HUMANS; LUNG DISEASES, INTERSTITIAL; MIDDLE AGED; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84872191279     PISSN: 01728172     EISSN: 1437160X     Source Type: Journal    
DOI: 10.1007/s00296-011-2220-4     Document Type: Article

References (15)

1. Dalakas MC (1991) Polymyositis, dermatomyositis and inclusion-body myositis. N Engl J Med 325:1487-1498
2. Marie I, Hachulla E, Cherin P, Dominique S, Hatron PY, Hellot MF, Devulder B, Herson S, Levesque H, Courtois H (2002) Interstitial lung disease in polymyositis and dermatomyositis. Arthritis Rheum 47:614-622 (Pubitemid 35461314)
3. Morganroth PA, Kreider ME, Werth VP (2010) Mycophenolate mofetil for interstitial lung disease in dermatomyositis. Arthritis Care Res (Hoboken) 62:1496-1501
4. Dold S, Justiniano ME, Marquez J, Espinoza LR (2007) Treatment of early and refractory dermatomyositis with infliximab: a report of two cases. Clin Rheumatol 26:1186-1188 (Pubitemid 46863976)
5. Sprott H, Glatzel M, Michel BA (2004) Treatment of myositis with etanercept (Enbrel), a recombinant human soluble fusion protein of TNF-Alpha type II receptor and IgG1. Rheumatology 43:524-526 (Pubitemid 38489376)
6. Uthman I, Sayad JE (2004) Refractory polymyositis responding to infliximab. Rheumatology 43:1198-1199
7. Labioche I, Liozon E, Weschler B, Loustaud-Ratti V, Soria P, Vidal E (2004) Refractory polymyositis responding to infliximab: extensied follow-up. Rheumatology 43:531-532 (Pubitemid 38489380)
8. Anandacoomarasamy A, Howe G, Manolios N (2005) Advanced refractory polymyositis responding to infliximab. Rheumatology 44:562-563 (Pubitemid 41511155)
9. Levine TD (2005) Retuximab in the treatment of dermatomyositis: an open-label pilot study. Arthritis Rheum 52:601-607 (Pubitemid 40216325)
10. Werth VP, Callen JP, Ang G, Sullivan KE (2002) Associations of tumor necrosis factor alpha and HLA polymorphisms with adult dermatomyositis: implications for a unique pathogenesis. J Invest Dermatol 119:617-620
11. Gabay C, Gay-Croisier F, Roux-Lombard P, Meyer O, Maineti C, Guerne PA et al (1994) Elevated serum levels of interleukin-1 receptor antagonist in polymyositis/dermatomyositis. A biologic marker of disease activity with a possible role in the lack of acute-phase protein response. Arthritis Rheum 37:1744-1751 (Pubitemid 24371875)
12. Shimizu T, Tomita Y, Son K, Nishinarita S, Sawada S, Horie T (2000) Elevation of serum soluble tumour necrosis factor receptors in patients with polymyositis and dermatomyositis. Clin Rheumatol 19:352-359
13. Kuru S, Inukai A, Liang Y, Doyu M, Takano A, Sobue G (2000) Tumor necrosis factor-Alpha expression in muscles of polymyositis and dermatomyositis. Acta Neuropathol (Berlin) 99:585-588 (Pubitemid 30201324)
14. Lundberg IE, Dastmalchi M (2002) Possible pathogenic mechanisms in inflammatory myopathies. Rheum Dis Clin N Am 28:799-822 (Pubitemid 36008553)
15. Kameda H, Takeuchi T (2006) Recent advances in the treatment of interstitial lung disease in patients with polymyositis/dermatomyositis. Endocr Metab Immune Disord Drug Targets 6:409-415 (Pubitemid 44941929)